Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

VIRAGE2 is an exploratory study aimed at refining the VCN-01 dosing regimen for possible use in a future pivotal Phase 3 trial in metastatic pancreatic ductal adenocarcinoma (PDAC). The update is pre-pivotal and mainly de-risks trial design rather than demonstrating efficacy. Overall, the near-term market impact is likely limited unless accompanied by efficacy or dosing outcomes.

Analysis

VIRAGE2 is an exploratory study aimed at refining the VCN-01 dosing regimen for possible use in a future pivotal Phase 3 trial in metastatic pancreatic ductal adenocarcinoma (PDAC). The update is pre-pivotal and mainly de-risks trial design rather than demonstrating efficacy. Overall, the near-term market impact is likely limited unless accompanied by efficacy or dosing outcomes.